الإحصائيات الأساسية
| LEI | 549300JEPFOD0K4D3I05 |
| CIK | 1438133 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tandem Diabetes Care, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissi |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 Tandem Diabetes Care, |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissi |
|
| August 6, 2025 |
Exhibit 10.1 Settlement, Mutual Release and Cross-License Agreement This Settlement, Mutual Release and Cross-License Agreement (“Agreement”) is made and entered into as of the 21 May 2025 (hereinafter referred to as “Effective Date”), by and among F. Hoffmann-La Roche AG, Grenzacherstr. 124, 4058 Basel, Switzerland, Roche Diabetes Care GmbH, Sandhofer Straße 116, 68305 Mannheim, Germany, Roche Di |
|
| August 6, 2025 |
Exhibit 99.1 Media Contact: 858-366-6900 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual Guidance San Diego, August 6, 2025 - Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financi |
|
| August 6, 2025 |
Exhibit 10.2 First Amendment to Settlement, Mutual Release and Cross-License Agreement This first amendment (the “First Amendment”) to that certain Settlement, Mutual Release and Cross-License Agreement with an Effective Date of 21 May 2025 (the “Agreement”) is made and entered into as of the 28 May 2025 (hereinafter referred to as the “Amendment Effective Date”), by and among F. Hoffmann-La Roche |
|
| May 29, 2025 |
Exhibit 1.01 to Form SD Tandem Diabetes Care, Inc. Conflict Minerals Report For the Reporting Period January 1 to December 31, 2024 This Conflict Minerals Report (“CMR”) has been prepared by Tandem Diabetes Care, Inc. on behalf of itself and its subsidiaries (collectively referred to as “Tandem,” the “Company,” “we,” “our” or “us”) for the reporting period January 1 to December 31, 2024 in accorda |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 12400 High Bluff Drive, San Diego, CA 92130 (Address of principal exe |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2025 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 Tandem Diabetes Care, |
|
| April 30, 2025 |
Tandem Diabetes Care Announces First Quarter 2025 Financial Results Exhibit 99.1 Media Contact: 858-366-6900 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces First Quarter 2025 Financial Results San Diego, April 30, 2025 - Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended Ma |
|
| April 30, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissi |
|
| April 30, 2025 |
Non-Employee Director Compensation Policy Exhibit 10.1 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Adopted and approved February 19, 2025 Tandem Diabetes Care, Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| February 26, 2025 |
by and between Tandem Diabetes Care, Inc. and Exhibit 10.26 EMPLOYMENT SEVERANCE AGREEMENT This Employment Severance Agreement (the “Agreement”) is made and entered into effective as of January 6, 2020 (the “Effective Date”), by and between Elizabeth Gasser (the “Employee”) and Tandem Diabetes Care, Inc. (the “Company”). R E C I T A L S A. The Board of Directors of the Company (the “Board”) believes the Company should provide the Employee wit |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36189 Tandem Diabetes Care, Inc. |
|
| February 26, 2025 |
by and between Tandem Diabetes Care, Inc. and Unomedical a/s. Exhibit 10.28 Amendment No. 2 to Distributor Agreement Unomedical a/s and Tandem Diabetes Care, Inc. [***]: Certain confidential portions of this exhibit were omitted by means of marking such portions with asterisks because the identified confidential portions (i) are not material, and (ii) would be competitively harmful if publicly disclosed. This amendment ( “Amendment No. 2”) is entered into ef |
|
| February 26, 2025 |
Exhibit 99.1 Media Contact: 858-366-6900 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance San Diego, February 26, 2025 - Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported |
|
| February 26, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commi |
|
| February 26, 2025 |
Tandem Diabetes Care, Inc. Insider Tradi Exhibit 19.1 INSIDER TRADING POLICY 1.PURPOSE 1.1. Statement of Policies and Procedures Governing Material Nonpublic Information and the Prevention of Insider Trading. The purchase or sale of securities while possessing material nonpublic (“inside”) information or the disclosure of inside information (“tipping”) to others who may trade in such securities is sometimes referred to as “insider tradin |
|
| February 26, 2025 |
Tandem Diabetes Care, Inc. Non-Employee Director Compe Exhibit 10.29 TANDEM DIABETES CARE, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Tandem Diabetes Care, Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the “Non-E |
|
| February 26, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Capillary Biomedical, LLC United States Sugarmate, LLC United States Tandem Diabetes Care Canada, Inc. Canada Tandem Diabetes Care Europe B.V. Netherlands Tandem Diabetes Care International Sarl Switzerland Tandem Diabetes Care Switzerland Sarl Switzerland |
|
| November 14, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| November 14, 2024 |
TNDM / Tandem Diabetes Care, Inc. / EMINENCE CAPITAL, LP Passive Investment SC 13G/A 1 p24-3294sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 Tandem Diabetes Care, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 875372203 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate b |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commis |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 Tandem Diabetes C |
|
| November 6, 2024 |
Exhibit 99.1 Media Contact: 858-366-6900 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Third Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance San Diego, November 6, 2024 - Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported |
|
| September 9, 2024 |
TNDM / Tandem Diabetes Care, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Tandem Diabetes Care, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 875372203 (CUSIP Number) August 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| August 1, 2024 |
Exhibit 99.1 Media Contact: 858-366-6900 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Second Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance San Diego, August 1, 2024 - Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported i |
|
| August 1, 2024 |
, by and between Tandem Diabetes Care, Inc. and 06/10/2024 Jean-Claude Kyrillos Dear Jean-Claude Kyrillos: Tandem Diabetes Care, Inc. |
|
| August 1, 2024 |
Agreement, dated May 21, 2024, by and between Tandem Diabetes Care, Inc. and Dexcom, Inc. AMENDED AND RESTATED COMMERCIALIZATION AGREEMENT This Amended and Restated Commercialization Agreement (this “Agreement”) is made and entered into effective as of May 21, 2024 (“Effective Date”) by and between Tandem Diabetes Care, Inc, having a principal place of business at 12400 High Bluff Drive, San Diego, CA 92130 (“Tandem”), and DexCom, Inc. |
|
| August 1, 2024 |
Amendment No. 1 to Distributor Agreement, dated May 10, 2024, by Amendment No. 1 to Distributor Agreement Unomedical a/s and Tandem Diabetes Care, Inc. This amendment ( “Amendment No. 1”) is entered into effective as of May 8, 2024 (the “Amendment Effective Date”) by and between Unomedical a/s, a Danish corporation having its principal place of business at Aaholmvej 1-3, Osted, 4320 Lejre, Denmark (“Company”), and Tandem Diabetes Care, Inc., a Delaware corporat |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 Tandem Diabetes Care, |
|
| August 1, 2024 |
21, 2024, by and between Tandem Diabetes Care, Inc. and De AMENDED AND RESTATED DEVELOPMENT AGREEMENT This Amended and Restated Development Agreement (this “Agreement”) is made and entered into effective as of May 21, 2024 (“Effective Date”) by and between Tandem Diabetes Care, Inc, having a principal place of business at 12400 High Bluff Drive, San Diego, CA 92130 (“Tandem”) and DexCom, Inc. |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissi |
|
| August 1, 2024 |
, 2024, by and between Tandem Diabetes Care, Inc. and Jean-Claude Kyrillos. EMPLOYMENT SEVERANCE AGREEMENT This Employment Severance Agreement (the “Agreement”) is made and entered into effective as of June 21, 2024 (the “Effective Date”), by and between Jean-Claude Kyrillos (the “Employee”) and Tandem Diabetes Care, Inc. |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2024 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissio |
|
| June 18, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 12400 High Bluff Drive, San Diego, CA 92130 (Address of principal exe |
|
| May 31, 2024 |
Exhibit 1.01 to Form SD Tandem Diabetes Care, Inc. Conflict Minerals Report For the Reporting Period January 1 to December 31, 2023 This Conflict Minerals Report (“CMR”) has been prepared by Tandem Diabetes Care, Inc. on behalf of itself and its subsidiaries (collectively referred to as “Tandem,” the “Company,” “we,” “our” or “us”) for the reporting period January 1 to December 31, 2022 in accorda |
|
| May 23, 2024 |
As Filed With the Securities and Exchange Commission on May 22, 2024 As Filed With the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 23, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Tandem Diabetes Care, Inc. |
|
| May 23, 2024 |
Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan TANDEM DIABETES CARE, INC. 2023 LONG-TERM INCENTIVE PLAN, AS AMENDED As approved by the Board of Directors on April 5, 2024 ARTICLE 1. PURPOSES OF THE PLAN 1.1Purposes. The purposes of the Plan are (a) to enhance the Company’s ability to attract and retain the services of qualified employees, officers, directors, consultants and other service providers upon whose judgment, initiative and efforts t |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| May 23, 2024 |
Tandem Diabetes Care, Inc. 2013 Employee Stock Purchase Plan, as amended. TANDEM DIABETES CARE, INC. 2013 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED As approved by the Board of Directors on April 5, 2024 ARTICLE 1 PURPOSE The purposes of the Plan are to (a) amend the 2013 Employee Stock Purchase Plan, originally adopted by the Board on October 29, 2013, and amended in March 2018 (b) to enhance the Company’s ability to attract and retain the services of Eligible Employees |
|
| May 16, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| May 2, 2024 |
Exhibit 99.1 Media Contact: 858-366-6900 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces First Quarter 2024 Financial Results and Updates Full Year 2024 Financial Guidance San Diego, May 2, 2024 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 Tandem Diabetes Care, |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 1, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissi |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissio |
|
| March 11, 2024 |
Form of Confirmation for Capped Call Transaction Exhibit 10.1 [Dealer name and address] Tandem Diabetes Care, Inc. 12400 High Bluff Drive San Diego, California 92130 [Dealer] [Base][Additional] Capped Call Transaction [], 2024 Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade Date specified below (the “Transacti |
|
| March 11, 2024 |
Exhibit 99.1 Tandem Diabetes Care Prices Upsized Private Placement of $275.0 Million of Convertible Senior Notes Due 2029 SAN DIEGO, Calif., March 6, 2024 – Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $275.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 (the “notes”) in a privat |
|
| March 11, 2024 |
Exhibit 4.1 TANDEM DIABETES CARE, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of March 8, 2024 1.50% Convertible Senior Notes due 2029 i Exhibit 4.1 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 13 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Design |
|
| March 11, 2024 |
Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes Exhibit 99.1 Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes SAN DIEGO, Calif., March 4, 2024 – Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today that it intends to offer, subject to market conditions and other factors, $250.0 million aggregate principal amount of its Convertible Senior Notes due 202 |
|
| February 21, 2024 |
Exhibit 10.25 10/31/2023 Mark Novara [REDACTED] Dear Mark Novara: Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) is pleased to offer you employment on the terms and conditions set forth below. 1. Position: You will serve in a full-time capacity as Executive Vice President & Chief Commercial Officer. You will report to John Sheridan, President & CEO. By signing this offer letter, you repres |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36189 Tandem Diabetes Care, Inc. |
|
| February 21, 2024 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following is a summary of all material characteristics of the capital stock of Tandem Diabetes Care, Inc., as set forth in our Amended and Restated Certificate of Incorporation, as amended, or our Charter, and our Amended and Restated Bylaws, as amended, or our Bylaws. References to "we," "us," and "our" refer to Tandem Diabetes Care, Inc. The summary d |
|
| February 21, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commi |
|
| February 21, 2024 |
Exhibit 99.1 Media Contact: 858-366-6900 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance San Diego, February 21, 2024 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported |
|
| February 21, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Capillary Biomedical, LLC United States Sugarmate, LLC United States Tandem Diabetes Care Canada, Inc. Canada Tandem Diabetes Care Europe B.V. Netherlands Tandem Diabetes Care Switzerland Sarl Switzerland |
|
| February 21, 2024 |
Exhibit 97 TANDEM DIABETES CARE, INC. CLAWBACK POLICY 1.GENERAL The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Tandem Diabetes Care, Inc., a Delaware corporation (the “Company”) has determined that it is in the best interests of the Company and its stockholders to adopt this Clawback Policy (this “Policy”) providing for the Company’s recoupment |
|
| February 14, 2024 |
TNDM / Tandem Diabetes Care, Inc. / EMINENCE CAPITAL, LP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Tandem Diabetes Care, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 875372203 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 13, 2024 |
TNDM / Tandem Diabetes Care, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02035-tandemdiabetescarein.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Tandem Diabetes Care Inc Title of Class of Securities: Common Stock CUSIP Number: 875372203 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t |
|
| February 9, 2024 |
TNDM / Tandem Diabetes Care, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Tandem Diabetes Care, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 875372203 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| December 11, 2023 |
Exhibit 10.1 December 1, 2023 David Berger [REDACTED] Re: Transition and Consulting Agreement (“Agreement”) Dear David: This letter sets forth the substance of the transition and consulting agreement (the “Agreement”) that Tandem Diabetes Care, Inc. (the “Company”) is offering to you to aid in your employment transition: 1.Resignation from Officer Roles. You understand and agree that, as of Decemb |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commis |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commis |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commis |
|
| November 1, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commis |
|
| November 1, 2023 |
Tandem Diabetes Care Announces Third Quarter 2023 Financial Results Exhibit 99.1 Media Contact: 858-255-6388 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Third Quarter 2023 Financial Results San Diego, November 1, 2023 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 Tandem Diabetes C |
|
| August 18, 2023 |
, 2023, entered into by and between Tandem Diabetes Care, Inc. and Brian Hansen. August 17, 2023 Brian Hansen [REDACTED] Re: Separation Agreement (“Agreement”) Dear Brian: We would like to assure a smooth transition for you and Tandem Diabetes Care, Inc. |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commiss |
|
| August 3, 2023 |
As Filed With the Securities and Exchange Commission on August 3, 2023 As Filed With the Securities and Exchange Commission on August 3, 2023 Registration No. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 Tandem Diabetes Care, |
|
| August 3, 2023 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TANDEM DIABETES CARE, INC. Tandem Diabetes Care, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies that (i) the Certificate of Incorporation of the Corporation was originally filed with the Secretary of State of Delaware on January 7, 2008, (ii) this Amended and R |
|
| August 3, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Tandem Diabetes Care, Inc. |
|
| August 3, 2023 |
Exhibit 99.1 Media Contact: 858-255-6388 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Second Quarter 2023 Financial Results and Updated Full Year 2023 Financial Guidance San Diego, August 3, 2023 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported |
|
| August 3, 2023 |
Amended and Restated Bylaws of the Registrant (as amended and currently in effect). Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF TANDEM DIABETES CARE, INC., a Delaware corporation As Updated Through August 1, 2023 ARTICLE I OFFICES Section 1. Registered Office. The registered office of Tandem Diabetes Care, Inc. (the “Corporation”) shall be fixed in the Corporation’s Certificate of Incorporation, as the same may be amended and/or restated from time to time (as so amended and/or res |
|
| August 3, 2023 |
Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan. Exhibit 10.1 TANDEM DIABETES CARE, INC. 2023 LONG-TERM INCENTIVE PLAN As approved by the Board of Directors on April 7, 2023 ARTICLE 1. PURPOSES OF THE PLAN 1.1Purposes. The purposes of the Plan are (a) to enhance the Company’s ability to attract and retain the services of qualified employees, officers, directors, consultants and other service providers upon whose judgment, initiative and efforts |
|
| August 3, 2023 |
Form of Restricted Stock Units Agreement under the 2023 Long-Term Incentive Plan. Exhibit 10.2 NOTICE OF RESTRICTED STOCK UNIT AWARD TANDEM DIABETES CARE, INC. 2023 LONG-TERM INCENTIVE PLAN Unless otherwise defined herein, the terms defined in the Tandem Diabetes Care, Inc. (the “Company”) 2023 Long-Term Incentive Plan (the “Plan”) shall have the same meanings in this Notice of Restricted Stock Unit Award (the “Notice”) and the attached Restricted Stock Unit Agreement (the “RSU |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissi |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 12400 High Bluff Drive, San Diego, CA 92130 (Address of principal exe |
|
| May 31, 2023 |
Exhibit 1.01 to Form SD Tandem Diabetes Care, Inc. Conflict Minerals Report For the Reporting Period January 1 to December 31, 2022 This Conflict Minerals Report (“CMR”) has been prepared by Tandem Diabetes Care, Inc. on behalf of itself and its subsidiaries (collectively referred to as “Tandem,” the “Company,” “we,” “our” or “us”) for the reporting period January 1 to December 31, 2022 in accorda |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| May 10, 2023 |
TNDM / Tandem Diabetes Care Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Tandem Diabetes Care, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 875372203 (CUSIP Number) April 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 Tandem Diabetes Care, |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| May 3, 2023 |
Exhibit 99.1 Media Contact: 858-255-6388 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces First Quarter 2023 Financial Results and Reaffirms Full Year 2023 Financial Guidance San Diego, May 3, 2023 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported i |
|
| May 3, 2023 |
Sr. Management Cash Bonus Plan. Exhibit 10.1 Tandem Diabetes Care, Inc. 2023 Sr. Management Cash Bonus Plan The Tandem Diabetes Care, Inc. 2023 Sr. Management Cash Bonus Plan (the “Bonus Plan”) has been designed to align plan participants with the business goals and strategies of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) and to further the objectives of the Company’s executive compensation program. This Bonus Plan i |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 10, 2023 |
TNDM / Tandem Diabetes Care Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Tandem Diabetes Care Inc. Title of Class of Securities: Common Stock CUSIP Number: 875372203 Date of Event Which Requires Filing of this Statement: March 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| February 22, 2023 |
Exhibit 99.1 Media Contact: 858-255-6388 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Fourth Quarter 2022 Financial Results and Full Year 2023 Financial Guidance San Diego, February 22, 2023 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commi |
|
| February 22, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization AMF Medical SA Switzerland Capillary Biomedical, LLC United States Sugarmate, LLC United States Tandem Diabetes Care Canada, Inc. Canada Tandem Diabetes Care Europe B.V. Netherlands |
|
| February 22, 2023 |
Tandem Diabetes Care Appoints New Chair of Board of Directors Exhibit 99.1 Media Contact: 858-255-6388 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Appoints New Chair of Board of Directors San Diego, February 22, 2023 – Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Rebecca Robertson as Chair o |
|
| February 22, 2023 |
Share Purchase Agreement by and Between Tandem Diabetes Care, Inc., and AMF Medical Share Purchase Agreement dated as of December 10, 2022 by and among each of the individuals and entities listed in (each a Seller and collectively the Sellers) Annex B and Tandem Diabetes Care, Inc. |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36189 Tandem Diabetes Care, Inc. |
|
| February 13, 2023 |
TNDM / Tandem Diabetes Care Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Tandem Diabetes Care, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 875372203 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 9, 2023 |
TNDM / Tandem Diabetes Care Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02006-tandemdiabetescarein.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Tandem Diabetes Care Inc. Title of Class of Securities: Common Stock CUSIP Number: 875372203 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box |
|
| January 23, 2023 |
Tandem Diabetes Care Completes Acquisition of Insulin Patch Pump Developer, AMF Medical Exhibit 99.1 Media Contact: 858-255-6388 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Completes Acquisition of Insulin Patch Pump Developer, AMF Medical SAN DIEGO – January 23, 2023 — Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced the completion of its |
|
| January 23, 2023 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2023 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commis |
|
| January 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commis |
|
| January 10, 2023 |
Tandem Diabetes Care Reports Preliminary, Unaudited 2022 Sales and Reaffirms 2023 Outlook Exhibit 99.1 Media Contact: 858-255-6388 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Reports Preliminary, Unaudited 2022 Sales and Reaffirms 2023 Outlook SAN DIEGO – January 10, 2023 – Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its preliminary, unau |
|
| December 13, 2022 |
Exhibit 99.1 Media Contact: 858-255-6388 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care to Acquire Insulin Patch Pump Developer, AMF Medical Acquisition Expands Addressable Market Opportunity and Complements Family of Insulin Delivery Offerings Conference Call Tuesday, December 13, 2022 at 8:00am ET The Sigi™ Patch Pump by A |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2022 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commi |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commis |
|
| November 2, 2022 |
Exhibit 99.1 Media Contact: 858-255-6388 [email protected] Investor Contact: 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Third Quarter 2022 Financial Results and Updated Full Year 2022 Financial Guidance San Diego, November 2, 2022 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reporte |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 Tandem Diabetes C |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissi |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 Tandem Diabetes Care, |
|
| August 3, 2022 |
Exhibit 10.1 CREDIT AGREEMENT Dated as of May 18, 2022 among TANDEM DIABETES CARE, INC., as the Borrower, THE SUBSIDIARY GUARANTORS FROM TIME TO TIME PARTY HERETO, as the Guarantors, BANK OF AMERICA, N.A., as Administrative Agent, a Swing Line Lender and an L/C Issuer, THE SUBSIDIARY GUARANTORS FROM TIME TO TIME PARTY HERETO, as the Guarantors, BANK OF AMERICA, N.A., as Administrative Agent, a Swi |
|
| August 3, 2022 |
Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Second Quarter 2022 Financial Results and Updated Full Year 2022 Financial Guidance San Diego, August 3, 2022 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes t |
|
| August 3, 2022 |
[Certain confidential portions of this agreement (marked with [***]) have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K because the Company has determined that such redacted information is (i) not material, and (ii) is the type of information the Company treats as private or confidential. |
|
| June 16, 2022 |
Tandem Diabetes Care Welcomes Two New Members to Board of Directors Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Welcomes Two New Members to Board of Directors San Diego, June 16, 2022 ? Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced the appointme |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissio |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 11075 Roselle Street, San Diego, CA 92121 (Address of principal execu |
|
| May 27, 2022 |
Exhibit 1.01 Tandem Diabetes Care, Inc. Conflict Minerals Report For the Reporting Period January 1 to December 31, 2021 This Conflict Minerals Report (?CMR?) has been prepared by Tandem Diabetes Care, Inc. on behalf of itself and its subsidiaries (collectively referred to as ?Tandem,? the ?Company,? ?we,? ?our? or ?us?) for calendar year 2021 pursuant to Rule 13p-1 promulgated under the Securitie |
|
| May 27, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| May 4, 2022 |
Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces First Quarter 2022 Financial Results and Updated Full Year 2022 Financial Guidance San Diego, May 4, 2022 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading global insulin delivery and diabet |
|
| May 4, 2022 |
NoSuchKey The specified key does not exist. edgar/data/1438133/000143813322000063/ex-24.htm QCWMN833GCDCCYFQ bdod5lPbsqGHhlJXmzpnJboCMjVjSzEmByazUtsEzpd8dnP/6bG51aklqKuHMouRSQev3jxR+AI= |
|
| May 4, 2022 |
Sr. Management Cash Bonus Plan. Exhibit 10.1 Tandem Diabetes Care, Inc. 2022 Sr. Management Cash Bonus Plan The Tandem Diabetes Care, Inc. 2022 Sr. Management Cash Bonus Plan (the ?Bonus Plan?) has been designed to align plan participants with the business goals and strategies of Tandem Diabetes Care, Inc. (?Tandem? or the ?Company?) and to further the objectives of the Company?s executive compensation program. This Bonus Plan i |
|
| May 4, 2022 |
POWER OF ATTORNEY The undersigned hereby constitutes and appoints Shannon M. Hansen, Leigh A. Vosseller, Christina X. Sun, and Rachel Malina, or any of them signing individually, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of Tandem Diabetes Care, Inc. (the "Company"), Forms 3, 4 and 5 in accor |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 Tandem Diabetes Care, |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| April 13, 2022 |
DEF 14A 1 a2022proxy-tndmdef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted b |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 30, 2022 |
PRE 14A 1 a2022proxy-tndmpre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: x Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted b |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2022 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissi |
|
| February 22, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Tandem Diabetes Care Canada, Inc. Canada Sugarmate Inc. United States |
|
| February 22, 2022 |
Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance San Diego, February 22, 2022 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes t |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2022 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commis |
|
| February 22, 2022 |
by and Between Tandem Diabetes Care, Inc. and ONE DEL MAR LLC Exhibit 10.36 LEASE BETWEEN ONE DEL MAR LLC AND TANDEM DIABETES CARE, INC. Exhibit 10.36 LEASE THIS LEASE is made as of May 10, 2021, by and between ONE DEL MAR LLC, a Delaware limited liability company, hereafter called ?Landlord,? and TANDEM DIABETES CARE, INC., a Delaware corporation, hereafter called ?Tenant.? ARTICLE 1. BASIC LEASE PROVISIONS Each reference in this Lease to the ?Basic Lease P |
|
| February 22, 2022 |
Exhibit 10.35 DISTRIBUTOR AGREEMENT [***]: Certain confidential portions of this exhibit were omitted by means of marking such portions with asterisks because the identified confidential portions (i) are not material, and (ii) would be competitively harmful if publicly disclosed. This Distributor Agreement (the ?Agreement?) is entered into effective as of January 14, 2022 (?Effective Date?), by an |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36189 Tandem Diabetes Care, Inc. |
|
| February 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2022 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commi |
|
| February 16, 2022 |
Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces FDA Clearance for the t:slim X2 Insulin Pump to Bolus Using the t:connect Mobile App First Smartphone App FDA cleared for Insulin Delivery on Both iOS and Android Operating Systems San Diego, Feb |
|
| February 11, 2022 |
TNDM / Tandem Diabetes Care Inc / Jackson Square Partners, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Tandem Diabetes Care Inc (Name of Issuer) Common (Title of Class of Securities) 875372203 (CUSIP Number) 12/31/2021 (Date of Event Which Re |
|
| February 11, 2022 |
TNDM / Tandem Diabetes Care Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Tandem Diabetes Care, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 875372203 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 10, 2022 |
TNDM / Tandem Diabetes Care Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01996-tandemdiabetescarein.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Tandem Diabetes Care Inc. Title of Class of Securities: Common Stock CUSIP Number: 875372203 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commis |
|
| November 3, 2021 |
Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Third Quarter 2021 Financial Results and Updated Full Year 2021 Sales Guidance Virtual R&D Day Scheduled for December 6, 2021 San Diego, November 3, 2021 - Tandem Diabetes Care, Inc. (NASDAQ: TND |
|
| November 3, 2021 |
OFFICE LEASE KILROY REALTY DEL MAR CORPORATE CENTRE III KILROY REALTY, L.P., a Delaware limited partnership, as Landlord, and TANDEM DIABETES CARE, INC., a Delaware corporation, as Tenant. TABLE OF CONTENTS Page ARTICLE 1 PREMISES, BUILDING, PROJECT, AND COMMON AREAS 5 ARTICLE 2 LEASE TERM; EXTENSION OPTIONS 8 ARTICLE 3 BASE RENT 8 ARTICLE 4 ADDITIONAL RENT 9 ARTICLE 5 USE OF PREMISES 18 ARTICLE 6 |
|
| November 3, 2021 |
Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 |
|
| September 17, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2021 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Comm |
|
| August 4, 2021 |
Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 Tand |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissi |
|
| August 4, 2021 |
Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 x7005 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Second Quarter 2021 Financial Results and Updated Full Year 2021 Sales Guidance San Diego, August 4, 2021 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabete |
|
| May 28, 2021 |
EX-1.01 2 exhibit101conflictminerals.htm EX-1.01 Exhibit 1.01 Tandem Diabetes Care, Inc. Conflict Minerals Report For the Reporting Period January 1 to December 31, 2020 This Conflict Minerals Report (“CMR”) has been prepared by Tandem Diabetes Care, Inc. (herein referred to as “Tandem,” “we,” “our” or “us”). This CMR for the reporting period January 1 to December 31, 2020 (the “Reporting Period”) |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 11075 Roselle Street, San Diego, CA 92121 (Address of principal execu |
|
| May 19, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2021 |
Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 Tan |
|
| May 5, 2021 |
Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 x7005 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces First Quarter 2021 Financial Results and Updated Full Year 2021 Sales Guidance San Diego, May 5, 2021 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes te |
|
| May 5, 2021 |
Tandem Diabetes Care, Inc. 2021 S Exhibit 10.2 Tandem Diabetes Care, Inc. 2021 Sr. Management Cash Bonus Plan The Tandem Diabetes Care, Inc. 2021 Sr. Management Cash Bonus Plan (the ?Bonus Plan?) has been designed to align plan participants with the business goals and strategies of Tandem Diabetes Care, Inc. (?Tandem? or the ?Company?) and to further the objectives of the Company?s executive compensation program. This Bonus Plan i |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2021 |
SECOND AMENDMENT TO OFFICE LEASE This SECOND AMENDMENT TO OFFICE LEASE (?Amendment?) is made as of March 11, 2021 (?Effective Date?), by and between TREA PACIFIC PLAZA, LLC, a Delaware limited liability company (?Landlord?), and TANDEM DIABETES CARE, INC. |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| February 24, 2021 |
Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 x7005 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Fourth Quarter and Full Year 2020 Financial Results and 2021 Financial Guidance San Diego, February 24, 2021 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diab |
|
| February 24, 2021 |
EX-21.1 5 ex211subsidiariesoftheregi.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Tandem Diabetes Canada Canada Sugarmate Inc. United States |
|
| February 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36189 Tandem Diabetes Care, Inc. |
|
| February 24, 2021 |
Exhibit 10.25 COMMERCIALIZATION AGREEMENT This Commercialization Agreement (this ?Agreement?) is made and entered into on November 20, 2020 (the ?Effective Date?) by and between Tandem Diabetes Care, Inc, having a principal place of business at 11075 Roselle St., San Diego, CA 92121 (?Tandem?) and DexCom, Inc., a Delaware corporation having a principal place of business at 6340 Sequence Drive, San |
|
| February 24, 2021 |
Exhibit 10.24 DEVELOPMENT AGREEMENT This Development Agreement (this ?Agreement?) is made and entered into on November 20, 2020 (the ?Effective Date?) by and between Tandem Diabetes Care, Inc, having a principal place of business at 11075 Roselle St., San Diego, CA 92121 (?Tandem?) and DexCom, Inc., a Delaware corporation having a principal place of business at 6340 Sequence Drive, San Diego, CA 9 |
|
| February 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2021 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commi |
|
| February 24, 2021 |
Amended and Restated Bylaws (as amended through February 4, 2021 and currently in effect). Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF TANDEM DIABETES CARE, INC., a Delaware corporation As Updated Through February 4, 2021 ARTICLE I OFFICES Section 1.Registered Office. The registered office of Tandem Diabetes Care, Inc. (the ?Corporation?) shall be fixed in the Corporation?s Certificate of Incorporation, as the same may be amended and/or restated from time to time (as so amended and/or re |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tandem Diabetes Care, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 875372203 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* Under the Securities Exchange Act of 1934 Tandem Diabetes Care, Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Titles of Class of Securities) 875372104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Tandem Diabetes Care Inc. Title of Class of Securities: Common Stock CUSIP Number: 875372203 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Tandem Diabetes Care Inc (Name of Issuer) Common (Title of Class of Securities) 875372203 (CUSIP Number) 12/31/2020 (Date of Event Which Req |
|
| February 8, 2021 |
Certificate of Amendment of the Amended and Restated Bylaws of Tandem Diabetes Care, Inc. EX-3.1 2 ex31certificateofamendment.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED BYLAWS OF TANDEM DIABETES CARE, INC., a Delaware corporation The undersigned hereby certifies that he is the duly elected, qualified and acting Secretary of Tandem Diabetes Care, Inc., a Delaware corporation (the “Corporation”), and that the Amended and Restated Bylaws of the Corporation |
|
| February 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 04, 2021 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commi |
|
| December 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2020 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commi |
|
| December 14, 2020 |
Tandem Diabetes Care Appoints Raj Sodhi to Board of Directors EX-99.1 2 exhibit991pressrelease.htm EX-99.1 Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 x7005 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Appoints Raj Sodhi to Board of Directors San Diego, December 14, 2020 – Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes |
|
| December 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* TANDEM DIABETES CARE INC (Name of Issuer) Common Stock (Title of Class of Securities) 875372203 (CUSIP Number) November 30, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| November 23, 2020 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2020 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commi |
|
| November 5, 2020 |
ARE-11025/11075 ROSELLE STREET, LLC EX-10.1 2 exhibit101-leaseamendm.htm EX-10.1 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this "Amendment") is made as of September 2, 2020, by and between ARE-11025/11075 ROSELLE STREET, LLC, a Delaware limited liability company ("Landlord"), and TANDEM DIABETES CARE, INC., a Delaware corporation ("Tenant"). RECITALS A.Landlord and Tenant are now parties to that certain Lease Agreeme |
|
| November 5, 2020 |
Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 x7005 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Third Quarter 2020 Financial Results and Updated Full Year 2020 Sales Guidance San Diego, November 5, 2020 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabet |
|
| November 5, 2020 |
EX-10.2 3 exhibit102-leaseamendm.htm EX-10.2 FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE (this "Amendment") is made as of September 2, 2020, by and between ARE-11025/11075 ROSELLE STREET, LLC, a Delaware limited liability company ("Landlord"), and TANDEM DIABETES CARE, INC., a Delaware corporation ("Tenant"). RECITALS A.Landlord and Tenant are now parties to that certain Lease Agreement |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commis |
|
| November 5, 2020 |
Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 |
|
| August 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2020 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commiss |
|
| August 21, 2020 |
Certificate of Amendment of the Amended and Restated Bylaws of Tandem Diabetes Care, Inc. EX-3.1 2 certificateofamendment.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED BYLAWS OF TANDEM DIABETES CARE, INC., a Delaware corporation The undersigned hereby certifies that he is the duly elected, qualified and acting Secretary of Tandem Diabetes Care, Inc., a Delaware corporation (the “Corporation”), and that the Amended and Restated Bylaws of the Corporation, as |
|
| July 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2020 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissio |
|
| July 31, 2020 |
Press release of Tandem Diabetes Care, Inc. dated July 29, 2020. |
|
| July 30, 2020 |
Form of Restricted Stock Unit Agreement Exhibit 10.1 RESTRICTED STOCK UNIT AGREEMENT TANDEM DIABETES CARE, INC. AMENDED AND RESTATED 2013 STOCK INCENTIVE PLAN You have been granted Restricted Stock Units (“RSUs”) by Tandem Diabetes Care, Inc. (the “Company”) subject to the terms, restrictions and conditions of the Tandem Diabetes Care, Inc. Amended and Restated 2013 Stock Incentive Plan (the “Plan”), the Notice of Restricted Stock Unit |
|
| July 30, 2020 |
Tandem Diabetes Care Appoints Peyton Howell to Board of Directors EX-99.1 2 exhibit991pressrelease.htm EX-99.1 Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 x7005 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Appoints Peyton Howell to Board of Directors San Diego, July 29, 2020 – Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes |
|
| July 30, 2020 |
Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 Tand |
|
| July 30, 2020 |
EX-99.1 2 exhibit991-pressreleas.htm EXHIBIT 99.1 Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 x7005 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Second Quarter 2020 Financial Results and Full Year 2020 Sales Guidance San Diego, July 30, 2020 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM |
|
| July 30, 2020 |
Tandem Diabetes Care, Inc. Amended and Restated 2013 Stock Incentive Plan. EX-10.2 3 ex102amended2013stockp.htm EXHIBIT 10.2 AMENDED 2013 STOCK PLAN Exhibit 10.2 TANDEM DIABETES CARE, INC. AMENDED AND RESTATED 2013 STOCK INCENTIVE PLAN As adopted by the Board of Directors on May 28, 2020 ARTICLE 1. PURPOSES OF THE PLAN 1.1 Purposes. The purposes of the Plan are (a) to amend and restate, in its entirety, the 2013 Stock Incentive Plan, originally adopted by the Board on Oc |
|
| July 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2020 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissio |
|
| July 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2020 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissio |
|
| July 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2020 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| June 25, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2020 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissio |
|
| June 25, 2020 |
Tandem Diabetes Care Acquires Sugarmate, a Popular Mobile App for People with Diabetes Exhibit 99.1 FOR IMMEDIATE RELEASE Tandem Diabetes Care Acquires Sugarmate, a Popular Mobile App for People with Diabetes San Diego, CA – June 24, 2020 – Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its acquisition of Sugarmate, a popular mobile app for people with diabetes who use insulin. Sugarmate will become a wholly own |
|
| June 18, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Expanded Pediatric Indication of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology San Diego, CA – June 17, 2020 – Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of an expanded ped |
|
| June 18, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2020 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissio |
|
| June 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2020 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| June 5, 2020 |
Tandem Diabetes Care Appoints Dr. Kathleen McGroddy-Goetz to Board of Directors Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 x7005 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Appoints Dr. Kathleen McGroddy-Goetz to Board of Directors San Diego, June 4, 2020 – Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today annou |
|
| June 1, 2020 |
Exhibit 1.01 Tandem Diabetes Care, Inc. Conflict Minerals Report For The Reporting Period January 1 to December 31, 2019 This Conflict Minerals Report (“CMR”) has been prepared by Tandem Diabetes Care, Inc. (herein referred to as “Tandem,” “we,” “our” or “us”). This CMR for the reporting period January 1 to December 31, 2019 (the “Reporting Period”) is presented to comply with the final conflict m |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 11075 Roselle Street, San Diego, CA 92121 (Address of principal execu |
|
| May 28, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2020 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| May 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2020 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| May 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 18, 2020 |
- DEFA14A ADDITIONAL PROXY MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 15, 2020 |
EXHIBIT 99.1 [Dealer] [Dealer Address] [Dealer Address] Opening Transaction To: Tandem Diabetes Care, Inc. 11075 Roselle Street San Diego, California 92121 Attention: David B. Berger, Esq. Telephone No.: (858) 255-6380 [A/C:] [ ] From: [Dealer] Re: [Base] [Additional] Call Option Transaction [Ref. No:] [Insert Reference Number] Date: May [15], 2020 Dear Ladies and Gentlemen: The purpose of this le |
|
| May 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2020 |
EX-4.1 2 ex41indenture.htm EX-4.1 INDENTURE TANDEM DIABETES CARE, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 15, 2020 1.50% Convertible Senior Notes due 2025 TABLE OF CONTENTS Page Article 1 Definitions Section 1.01 . Definitions. 1 Section 1.02 . References to Interest 12 Article 2 Issue, Description, Execution, Registration and Exchange of Notes 12 Section 2.01 |
|
| April 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2020 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissi |
|
| April 30, 2020 |
Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 x7005 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces First Quarter 2020 Financial Results Second Quarter 2020 Sales Guidance Provided, Annual Guidance Withdrawn San Diego, April 30, 2020, - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading |
|
| April 30, 2020 |
Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 Tan |
|
| April 30, 2020 |
Exhibit 10.1 LICENSE AGREEMENT [***]: Certain confidential portions of this exhibit were omitted by means of marking such portions with asterisks because the identified confidential portions (i) are not material, and (ii) would be competitively harmful if publicly disclosed. THIS LICENSE AGREEMENT (this “Agreement”) dated as of July 14, 2016 (the “Effective Date”), is entered into between TypeZero |
|
| April 30, 2020 |
Tandem Diabetes Care, Inc. 2020 Senior Management Cash Bonus Plan. Exhibit 10.2 Tandem Diabetes Care, Inc. 2020 Sr. Management Cash Bonus Plan The Tandem Diabetes Care, Inc. 2020 Sr. Management Cash Bonus Plan (the “Bonus Plan”) has been designed to align plan participants with the business goals and strategies of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) and to further the objectives of the Company’s executive compensation program. This Bonus Plan i |
|
| April 15, 2020 |
TNDM / Tandem Diabetes Care, Inc. DEF 14A - - DEF 14A PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 15, 2020 |
TNDM / Tandem Diabetes Care, Inc. DEFA14A - - DEFA14A DEFA14A 1 a2020proxycards-defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted |
|
| February 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36189 Tandem Diabetes Care, Inc. |
|
| February 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2020 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commi |
|
| February 24, 2020 |
EX-99.1 2 exhibit991-pressreleas.htm EXHIBIT 99.1 Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 x7005 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Fourth Quarter and Full Year 2019 Financial Results and 2020 Financial Guidance San Diego, February 24, 2020 - Tandem Diabetes Care, Inc. ( |
|
| February 24, 2020 |
Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK The following is a summary of all material characteristics of the capital stock of Tandem Diabetes Care, Inc., as set forth in our Amended and Restated Certificate of Incorporation, as amended, or our Charter, and our Amended and Restated Bylaws, as amended, or our Bylaws. References to "we," "us," and "our" refer to Tandem Diabetes Care, Inc. The summary d |
|
| February 24, 2020 |
Exhibit 10.36 LEASE Agreement Between AMERI SHORE LLC an Idaho limited liability company and TANDEM DIABETES CARE, INC. a Delaware corporation for 1500 W. Shoreline Drive Boise, Idaho 83702 November 14, 2019 Exhibit 10.36 TABLE OF CONTENTS 1 BASIC LEASE TERMS 4 2 CERTAIN DEFINITIONS 6 3 LEASE OF PREMISES 8 4 CONDITION OF PREMISES 8 5 PARKING AREA 8 6 OWNER’S OTHER LANDS 9 6.1 Redevelopment of Nort |
|
| February 12, 2020 |
TNDM / Tandem Diabetes Care, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Tandem Diabetes Care Inc Title of Class of Securities: Common Stock CUSIP Number: 875372203 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| February 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* TANDEM DIABETES CARE INC (Name of Issuer) Common Stock (Title of Class of Securities) 875372203 (CUSIP Number) January 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| January 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tandem Diabetes Care (Name of Issuer) Common Stock (Title of Class of Securities) 875372203 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| December 13, 2019 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces FDA Clearance of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology Automated Insulin Dosing Software First to Receive New Classification by FDA San Diego, CA - December 13, 2019 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S |
|
| December 13, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2019 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commi |
|
| December 6, 2019 |
TNDM / Tandem Diabetes Care, Inc. CORRESP - - 11075 Roselle Street San Diego, California 92121 December 6, 2019 Via EDGAR Submission U. |
|
| November 19, 2019 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2019 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commi |
|
| November 4, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2019 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commis |
|
| November 4, 2019 |
Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 x7005 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Third Quarter 2019 Financial Results and Updated 2019 Financial Guidance San Diego, November 4, 2019 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes tec |
|
| November 4, 2019 |
Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 |
|
| August 1, 2019 |
TNDM / Tandem Diabetes Care, Inc. S-8 - - S-8 AUGUST 2019 As Filed With the Securities and Exchange Commission on August 1, 2019 Registration No. |
|
| August 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2019 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissi |
|
| August 1, 2019 |
EX-99.1 2 exhibit991-pressreleaseq2e.htm Exhibit 99.1 Media Contact: Steve Sabicer 714-907-6264 [email protected] Investor Contact: Susan Morrison 858-366-6900 x7005 [email protected] FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Second Quarter 2019 Financial Results and Updated 2019 Financial Guidance San Diego, August 1, 2019 - Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a l |
|
| August 1, 2019 |
FIRST AMENDMENT TO OFFICE LEASE This FIRST AMENDMENT TO OFFICE LEASE ("Amendment'') is made as of May 15, 2019 ("Effective Date"), by and between TRBA PACIFIC PLAZA, LLC, a Delaware limited liability company ("Landlord''), and TANDEM DIABETES CARE, INC. |
|
| August 1, 2019 |
Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 Tand |
|
| June 19, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2019 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commissio |
|
| June 14, 2019 |
TNDM / Tandem Diabetes Care, Inc. DEFA14A - - DEFA14A DEFA14A 1 tndm-defa14a20190612.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| June 10, 2019 |
EX-99 2 tndm-ex9916.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Tandem Diabetes Care Reports Positive Results from Two Studies of the t:slim X2 Insulin Pump with Control-IQ Technology Significant Time-in-Range Improvements Demonstrated in Adult and Pediatric Age Groups San Francisco, CA – June 9, 2019 – Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technolog |
|
| June 10, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2019 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission |
|
| June 4, 2019 |
TNDM / Tandem Diabetes Care, Inc. DEFA14A - - DEFA14A ADDITIONAL PROXY MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 30, 2019 |
TNDM / Tandem Diabetes Care, Inc. DEFA14A - - DEFA14A_ADDITIONAL PROXY MATERIALS DEFA14A 1 tndm-defa14a20190530.htm DEFA14AADDITIONAL PROXY MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commis |
|
| May 30, 2019 |
Exhibit 1.01 Tandem Diabetes Care, Inc. Conflict Minerals Report For The Reporting Period January 1 to December 31, 2018 This Conflict Minerals Report (“CMR”) has been prepared by Tandem Diabetes Care, Inc. (herein referred to as “Tandem,” “we,” “our” or “us”). This CMR for the reporting period January 1 to December 31, 2018 (the “Reporting Period”) is presented to comply with the final conflict m |
|
| May 30, 2019 |
TNDM / Tandem Diabetes Care, Inc. SD - - SD_TNDM_2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 11075 Roselle Street, San Diego, CA 92121 (Address of principal execu |
|
| May 23, 2019 |
TNDM / Tandem Diabetes Care, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
